Abstract：Sodium-glucose cotransporter 2 (SGLT-2) inhibitor is a kind of novel hypoglycemic drug. It inhibits the reabsorption of glucose from the proximal renal tubules, leading to increased urine sugar and decreased plasma glucose level. Several cardiovascular outcome trials have proved that SGLT-2 inhibitor has significant cardiovascular benefits for both diabetic and nondiabetic patients, especially it can significantly reduce the risk of cardiovascular death or hospitalization due to heart failure (HF) in HF patients. However, its mechanism has not been completely clear. It may be associated with its improvement of heart’s workload, myocardial energy metabolism, ventricular remodeling and myocardial fibrosis, and its effects of protecting the kidney and maintaining heart ion homeostasis. This article reviews the potential mechanism and clinical research progress of SGLT-2 inhibitors in the treatment of HF.
